Allogene Updated Phase 1 Data In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO

Allogene Therapeutics (ALLO) presented promising Phase 1 TRAVERSE trial data for ALLO-316 in treating advanced renal cell carcinoma (RCC). The study demonstrated a 31% confirmed response rate in patients with CD70 TPS ≥50%, with four out of five confirmed responders maintaining ongoing responses, including one lasting over 12 months. The trial enrolled 22 heavily pretreated patients, with 20 receiving ALLO-316 treatment. Using the proprietary Dagger technology, patients received standard lymphodepletion followed by a single dose of 80 million AlloCAR T cells. The safety profile was manageable, with main adverse events including cytokine release syndrome (68%, no grade ≥3), neutropenia (68%), and decreased white blood cell count (68%). The treatment showed particular efficacy in patients with high CD70 expression, marking a significant advancement in allogeneic CAR T therapy for solid tumors.

https://www.stocktitan.net/news/ALLO/allogene-therapeutics-provides-updated-phase-1-data-highlighting-omyiebb59kxq.html